CS and malaria: The pre-erythrocytic RTS,S/AS01 vaccine (GSK) contains portions of the Plasmodium falciparum circumsporozoite (CS) protein and has been shown to be effective in reducing the malaria burden in children when used alongside other malaria interventions in phase II and III clinical trials [5–10].